
Oncology NEWS International
- Oncology NEWS International Vol 4 No 5
- Volume 4
- Issue 5
Suit to Test Rights of Physicians to Receive Info on Off-Label Drug Use
WASHINGTON--The Washington Legal Foundation (WLF), a public interest group, has claimed that the FDA violated the First Amendment rights of physicians by denying them access to information about the off-label use of certain oncologic drugs.
WASHINGTON--The Washington Legal Foundation (WLF), a public interestgroup, has claimed that the FDA violated the First Amendment rightsof physicians by denying them access to information about theoff-label use of certain oncologic drugs.
WLF's suit arises from an action taken by the FDA that preventedBristol-Myers Squibb Co.from giving physicians complimentary copiesof The Chemotherapy Sourcebook, edited by Michael Perry, and chaptersfrom Cancer: Principles and Practice of Oncology, by Vincent DeVita,Samuel Hellman, and Steven Rosenberg.
Federal Judge Royce Lamberth denied the FDA's motion to dismissthe suit, thus clearing the way for a trial, which will be thefirst constitutional test of the agency's criteria to discouragewhat it views as improper promotion of drugs by means of distributionof legitimate medical educational material.
Articles in this issue
about 31 years ago
Genetic Therapy Gets NIH Patentabout 31 years ago
Fusion Product Delivers Potent Toxin to Malignant Cellsabout 31 years ago
Retinoic Acid May Enhance Chemo In Ovarian Ca Cellsabout 31 years ago
Compounds Block ras Gene Function Compounds Block ras Gene Functionabout 31 years ago
Companies Merge to Form NeXstarabout 31 years ago
Antiangiogenesis Tested in Pediatric Tumorsabout 31 years ago
Delivery of Effective Cyclophosphamide Metabolite Could Reduce Toxicityabout 31 years ago
New Director Attends Office of Alternative Medicine Advisory MeetingNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content


130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
















































